
|Videos|July 23, 2013
Episode 6 - Addressing the Gaps in Care for Hemophilia Patients
Advertisement
Delivering the optimal care to patients with hemophilia is often a challenge, both clinically and financially. According to Patrick Fogarty, MD, the individuals who are best fit to execute treatment guidelines are those who practice at specialty hemophilia treatment centers, as they are able to provide on-site multidisciplinary, comprehensive care.
However, the panelists conclude that there are still gaps in current treatment guidelines that require addressing. In an effort to provide the best of care to all patients with hemophilia, regardless of geography, strategies such as home care, satellite clinics, and increased patient education have been implemented into contemporary treatment paradigms.
Advertisement
Related to this article

HHS enforcement discretion lets state pharmacies compound BPC-157 and other peptides amid rulemaking and legal challenges.

HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.

At AMCP Nexus 2026, payers said evidence, differentiation, and delivery now matter as much as FDA approval.

A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers

PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.

Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.

Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Machine Learning Has High Accuracy, Little Prospective Validation in MPNs
3
The Next Decade of Cancer Care Is Coming Home: Who Will Be in the Driver’s Seat?
4
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
5



















